Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...
GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...
the Food and Drug Administration said. Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback